Mineralys Therapeutics Inc. (MLYS) Statistics & Valuation Metrics - Stocknear

Mineralys Therapeutics In...

NASDAQ: MLYS · Real-Time Price · USD
38.06
-2.40 (-5.93%)
At close: Oct 03, 2025, 3:59 PM
38.50
1.16%
After-hours: Oct 03, 2025, 07:30 PM EDT

Mineralys Therapeutics Statistics

Share Statistics

Mineralys Therapeutics has 66.3M shares outstanding. The number of shares has increased by 33.21% in one year.

66.3M
33.21%
1.72%
99.99%
46.13M
50
n/a

Short Selling Information

The latest short interest is 7.58M, so 9.77% of the outstanding shares have been sold short.

7.58M
9.77%
12.28%
1.77

Valuation Ratios

The PE ratio is -3.36 and the forward PE ratio is -15.27. Mineralys Therapeutics's PEG ratio is -0.04.

-3.36
-15.27
0
223.8
3.12
-3.59
-0.04
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Mineralys Therapeutics.

n/a
n/a
n/a
n/a

Financial Position

The company has a current ratio of 14.02, with a Debt / Equity ratio of 0.

14.02
14.02
0
n/a
n/a
0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

n/a
n/a
n/a
n/a
$-3.49M
51
0
n/a

Taxes

n/a
0%

Stock Price Statistics

The stock price has increased by 174.21% in the last 52 weeks. The beta is 0.4, so Mineralys Therapeutics's price volatility has been higher than the market average.

0.4
174.21%
25.24
16.13
62.11
1,531,190

Income Statement

n/a
-43K
-192.4M
-177.81M
-192.36M
-192.4M
-3.66
Full Income Statement

Balance Sheet

The company has 114.09M in cash and 0 in debt, giving a net cash position of 114.09M.

114.09M
n/a
n/a
-302.52M
335.72M
313.1M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -166.31M and capital expenditures -96K, giving a free cash flow of -166.41M.

-166.31M
-96K
-166.41M
-3.43
Full Cash Flow Statement

Margins

n/a
n/a
n/a
n/a
n/a
n/a
n/a

Dividends & Yields

MLYS does not appear to pay any dividends at this time.

n/a
n/a
n/a
n/a
n/a
n/a
Dividend Details

Analyst Forecast

The average price target for MLYS is $46.5, which is 22.2% higher than the current price. The consensus rating is "Buy".

$46.5
22.2%
Buy
6
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

n/a
n/a
n/a
n/a

Scores

67.07
2